ovarian cancer
Conditions
Interventions
PEG-rhG-CSF group:After 24 hours of chemotherapy, and 12 days before the next cycle of chemotherapy, subcutaneous injection of Jinyouli (PEG-rhG-CSF) 6mg
Sponsors
The Fourth Hospital of Hebei Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years old; 2. Breast cancer patients diagnosed by pathology or histology; 3. Patients who plan to receive receive chemotherapy, and use jinyuli prophylactically after chemotherapy; 4. Patients with good mental awareness, understand the clinical Investigate and voluntarily join the study and sign an informed consent; 5. Researchers believe that patients can benefit.
Exclusion criteria
Exclusion criteria: 1. Those who have been confirmed to be allergic to pegfilgrastim or rhG-CSF and/or its excipients; 2. Pregnant or lactating women and women who plan to become pregnant during clinical observation; 3. Other patients considered unsuitable by doctors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence rate of FN; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of grade IV neutropenia;Incidence and duration of chemotherapy delay (for any reason, chemotherapy delay time is greater than or equal to 3 days);Incidence of chemotherapy dose reduction;Relative dose intensity; | — |
Countries
China
Contacts
Public ContactShan Kang
The Fourth Hospital of Hebei Medical University
Outcome results
None listed